Cutler Group LP Avadel Pharmaceuticals PLC Transaction History

Cutler Group LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 18, 2023	BUY	$8.48 - $16.48 $6,784 - $13,184	800 New	800 $13,000
Q2 2022 Aug 04, 2022	SELL	$1.07 - $6.95 $2,464 - $16,005	-2,303 Reduced 76.74%	698 $1,000
Q1 2022 Apr 14, 2022	SELL	$5.46 - $8.29 $3,101 - $4,708	-568 Reduced 15.91%	3,001 $20,000
Q4 2021 Jan 18, 2022	BUY	$7.34 - $11.18 $26,196 - $39,901	3,569 New	3,569 $28,000
Q1 2021 Apr 26, 2021	SELL	$6.61 - $10.07 $661 - $1,007	-100 Closed	0 $0
Q3 2020 Oct 27, 2020	SELL	$5.02 - $8.98 $2,510 - $4,490	-500 Reduced 83.33%	100 $0
Q2 2020 Jul 22, 2020	BUY	$7.25 - $11.75 $4,350 - $7,050	600 New	600 $4,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.